anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: To investigate the actual cost of hematuria evaluation using nationally representative claims data, given that the workup for hematuria burdens the healthcare system with significant associated costs. We hypothesized that evaluation with contrast-enhanced computed tomography (CT) confers more cost to hematuria evaluation than renal ultrasound (US).
METHODS: Using a national, privately insured database (MarketScan), we identified all individuals with an incident diagnosis of hematuria. We included patients who underwent cystoscopy and upper tract imaging within 3 months of diagnosis. We tabulated the costs of the imaging study as well as the total healthcare cost per patient. A multivariable model was developed to evaluate patient factors associated with total healthcare costs.
RESULTS: We identified 318,680 patients with hematuria who underwent evaluation. Median costs associated with upper tract imaging were $362 overall, $504 for CT with contrast, $163 for US, $680 for magnetic resonance imaging (MRI), $283 for CT without contrast, and $294 for retrograde pyelogram. Median cystoscopy cost was $283. Total healthcare costs per patient were highest when utilizing MRI and CT imaging. When adjusted for comorbidities, the use of any imaging other than ultrasound was associated with higher costs.
CONCLUSIONS: In this nationally representative analysis, hematuria evaluation confers a significant cost burden, while the primary factor associated with higher costs of screening was imaging type. Based upon reduced cost of US-based strategies, further investigation should delineate its cost-effectiveness in the diagnosis of urological disease.
PURPOSE:To provide an agent for deodorizing a permanent wave lotion containing a mercapto compound as a main agent, by using one or more germanium compounds, antimony compounds or bismuth compounds as a component. CONSTITUTION:A deodorizing agent consisting of one or more germanium compounds, antimony compounds or bismuth compounds (e.g. germanium dioxide, antimony chloride, etc.) is added to a permanent wave lotion containing a mercapto compound as a main agent. The characteristic ill-odor of mercapto compound and the unagreeable smell and after-odor of hydrogen sulfide can be removed easily without lowering the merits of a permanent wave lotion containing a mercapto compound having strong reducing power, e.g. thioglycolic acid, cysteine, etc. as a main agent. Furthermore, the deodorizing agent hardly forms a complex with the mercapto compound, and consequently, the blocking of the thiol group and the lowering of the waveforming capability can be prevented.
Participants in condition 3 will not receive any health promotion services during the skills training or follow-up period beyond what is offered at their respective institution. They will also be excluded from any group trainings similar to START NOW. For ethical reasons and to increase study-related commitment, they will be provided with the web-based pure self-help training after completion of the study. Institution staff will receive the first block of the pretraining and material from the second block after the end of the intervention. Supervision for participating caretakers and facilitators will not be provided during the intervention phase.
Rufinamide is a triazole derivative structurally unrelated to currently marketed antiepileptic drugs (AEDs). Rufinamide has the chemical name 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4 carboxamide. It has an empirical formula of C10H8F2N4O and a molecular weight of 238.20. The drug substance is a white crystalline powder. Rufinamide is practically insoluble in water, slightly soluble in tetrahydrofuran and in methanol, and very slightly soluble in ethanol and in acetonitrile.

    

Rufinamide Oral Suspension is available for oral administration as a liquid containing rufinamide, USP at a concentration of 40 mg/mL. Inactive ingredients include: anhydrous citric acid, hydroxyethyl cellulose, methylparaben, microcrystalline cellulose and carboxymethylcellulose sodium, poloxamer, potassium sorbate, propylene glycol, propylparaben, purified water, simethicone emulsion, sodium hydroxide, sorbitol solution and orange flavoring.
Compositions and processes for forming radiopaque polymeric articles are disclosed. In one embodiment, radiation inspection apparatuses and methods are then used to determine the presence and attributes of such radiopaque polymeric articles. A radiopaque polymeric article of the present invention can be created by mixing a radiopaque material, such as barium, bismuth, tungsten or their compounds, with a powdered polymer, pelletized polymer or liquid solution, emulsion or suspension of a polymer in solvent or water. In addition to creating radiation detectable objects, the radiopaque polymeric materials of the present invention can be used to create radiation protective articles, such as radiation protective garments and bomb containment vessels. Enhanced radiation protection can also be achieved through the use of nano-materials. The principals of the present invention can be used to provide protection against other types of hazards, including fire, chemical, biological and projectile hazards.
PURPOSE:To obtain the title composition capable of dyeing the hair in blackish brown natural color tone, having excellent fastness to sunlight and resistance to washing by combining a p-diamine with 2,4-diaminophenol or a salt thereof in a fixed molar ratio. CONSTITUTION:A p-diamine selected from p-diamine derivative shown by the formula (R1 is H, alkyl, hydroxyalkyl, etc.; R2 is H, alkyl or hydroxyalkyl; R1 and R2 are H, alkyl or hydroxyalkyl; R3 and R4 are H, alkyl, alkoxy, halogen, COOH, etc.) and salts thereof is combined with 2,4-diaminophenol or a salt thereof in the molar ratio of (100:1)-(1:5) to give an air oxidation hair dyeing agent composition of one-agent type. Further addition of a specific m-diamine, phenol or naphthol to cause a coupling reaction to provide excellent color tone. Furthermore addition of direct dye gives a natural color tone having extremely high chroma.
The present invention relates to genetic engineering and can be used in biotechnology, medicine and agriculture. The invention requires the construction of a 3165bp gene therapy DNA vector VTvaf17 for the genetic modification of animal and human cells containing the nucleotide sequence SEQ ID No. 1. The method of constructing the 3165bp gene therapy DNA vector VTvaf17 comprises first constructing a 4182bp vector containing the 1188bp promoter region of human elongation factor EF1A with intrinsic enhancer, a 35bp polylinker with sites for restriction endonucleases BamHI, EcoRV, Sail, HindIII, KpnI, EcoRI, a polyadenylation sequence of the human growth factor, a 466bp transcription terminator and a polyadenylation sequence of the human growth factor, the 136bp regulatory element RNA-OUT of transposon Tn10 allowing antibiotic-free positive selection, a 1299bp replication origin for autonomous replication with single nucleotide substitution to increase vector production in the cells of most e. The stated objectives can be achieved by obtaining the E.coli strain SCS110-AF to generate the gene therapy DNA vector VTvaf17 or a gene therapy DNA vector based thereon that allows for antibiotic-free positive selection. The method for obtaining the E.coli strain SCS110-AF to generate the gene therapy DNA vector VTvaf17 or a gene therapy DNA vector based thereon comprises constructing a linear DNA fragment of 64bp containing the regulatory element RNA-IN of transposon Tn10, 1422bp fructan sucrase gene sacB (the product of which ensures selection IN sucrose-containing medium) that allows antibiotic-free positive selection, the 763bp chloramphenicol resistance gene catR required for cloning of the strain where homologous recombination occurs, the two homologous sequences 329bp and 233bp ensuring homologous recombination IN the region of the gene recA at the same time as the gene inactivation, transforming the E.coli cells by electroporation and selecting clones that survive IN medium containing 10. mu.g/ml chloramphenicol. Coli strain SCS110-AF/VTvaf17 (registered at russian national collections of industrial microorganisms under accession number B-12990, international depository number NCIMB 42801) carrying gene therapy DNA vector VTvaf17 was also constructed for its further development allowing antibiotic-free selection. The method for obtaining E.coli strain SCS110-AFA/Tvaf17 (registered at Russian national collections of Industrial microorganisms under the number B-12990, International Collection number NCIMB 42801) carrying gene therapy DNA vector VTvaf17 comprises preparing electrocompetent cells of E.coli strain SCS110-AF and electroporating these cells with gene therapy DNA vector VTvaf 17. Thereafter, the cells were poured into agar plates (petri dishes) with a selective medium containing yeast extract, peptone, 6% sucrose and 10. mu.g/ml chloramphenicol.
Infertile women with diagnosis of arcuate and septate uterus based on Hystro-salpingography were recruited. All women were examined by Three dimensional ultrasound on day 22 cycle to allow for better delineation of the uterine contour. The outer and inner fundal contours and the length of the fundal notch were examined by Three dimensional ultrasound in the mid-coronal view of the multi-planar and multi-slice display of the uterus. The final diagnosis of the anomalies was based on combined hysteroscopy/laparoscopy examination, the gold standard.
Inflammatory breast cancer (IBC) is a rare, poorly understood and particularly aggressive form of breast cancer characterized by diffuse erythema and edema/peau d orange of the breast. The proposed case-control study of risk factors for IBC will include approximately 400 IBC cases accrued over a two-year period in centers in four countries in North Africa (the major cancer center and selected private clinicians in Tunisia, the major cancer center in Egypt, 2 cancer centers in Algeria, and 2 cancer centers in Morocco). Two control groups will be included: 1) 400 non-IBC breast cancer cases and; 2) 400 visitor controls (excluding those with breast, ovarian, endometrial, and nasopharyngeal cancers) in the study hospitals. The study will involve the administration of a questionnaire, anthropometric measurements, and saliva collection for all study subjects. In addition, digital photographs of the breasts will be collected for IBC cases, and a clinical examination form and paraffin-embedded tumor tissue will be collected for IBC cases and non-IOBC breast cancer controls. The study will be conducted as a consortium, with form development and translation coordinated at the National Cancer Institute (USA). A review of study procedures will be done after the first three months of data collection. The National Cancer Institute (NCI)-Division of Cancer Epidemiology and Genetics (DCEG), NCI-Office of International Affairs (OIA), University of Michigan, and International Breast Cancer Research Foundation (IBCRF) will provide funding for the project.
ABSTRACTDeficits in episodic memory have been reported in various psychiatric conditions, including Major Depressive Disorder (MDD). Many widely used episodic memory tests do not have the ability to distinguish between impaired memory of separate components of a real-life event (e.g., what happened, where it happened and when), and impaired binding of such real-life features. To address this issue, a naturalistic, real-world What-Where-When memory task was employed to assess the nature of episodic memory impairments in MDD. A validation study established that the task is sensitive to age-related episodic memory changes, and that intentional encoding does not invalidate the task. The main study then compared the performance of patients with depression and control participants on the intentionally encoded WWW task. Patients with MDD presented an overall episodic memory impairment arising from deficits in object memory and the ability to bind objects to temporal context. Taken together, our study confirms the episodic memory impairment in MDD, by providing evidence of deficient object memory and reduced ability to bind temporal context to objects in patients. Our naturalistic WWW task presents a promising approach for thorough identification of the nature of episodic memory impairments, under a real-world environment, in various conditions, including MDD.
Emerging evidence has shown the association between female reproductive histories (e.g., menarche age, parity, premature and early menopause) and the risk of dementia. However, little attention has been given to infertility and pregnancy loss. To examine the associations of infertility, recurrent miscarriages, and stillbirth with the risk of dementia, this study used data from four cohorts in the International Collaboration for a Life Course Approach to Reproductive Health and Chronic Disease Events. Women with data on at least one of the reproductive exposures of interest, dementia, and all covariates were included. Histories of infertility, miscarriage, and stillbirth were self-reported. Dementia (including Alzheimer's disease) was identified through surveys, aged care, pharmaceutical, hospital, and death registry data. Cause-specific Cox regression models were used to estimate the hazard ratios of dementia, accounting for well-established risk factors of dementia, study variability, and within-study correlation. Overall, 291,055 women were included at a median (interquartile range) age of 55.0 (47.0-62.0) at baseline. During the median (interquartile range) follow-up period of 13.0 (12.0-14.0) years, 3334 (1.2%) women developed dementia. Compared to women without stillbirth, a history of recurrent stillbirths (≥ 2) was associated with 64% higher risk of dementia (adjusted hazard ratio = 1.64, 95% confidence interval: 1.46-1.85). Compared to women without miscarriage, women with recurrent miscarriages (≥ 3) were at 22% higher risk of dementia (adjusted hazard ratio = 1.22, 95% confidence interval: 1.19-1.25). These findings suggest that recurrent stillbirths is a risk factor for dementia and may need to be considered in risk assessment of dementia in women.
Participants received a maximum of 15 milligrams (mg) ecallantide in stages. Intravenous (IV) infusion of 0.6 milligrams per milliliter (mg/mL) ecallantide was administered at 2.92 milliliters per minute (mL/min) for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of cardiopulmonary bypass (CPB), whichever came first. At the termination of the initial infusion, a second infusion of 0.4 mg/mL ecallantide was started at 38 milliliters per hour (mL/hr) for 4 hours.
Digitalization is increasingly finding its way into intensive care units and with it artificial intelligence (AI) for critically ill patients. One promising area for the use of AI is in the field of acute kidney injury (AKI). The use of AI is primarily focused on the prediction of AKI, but further approaches are also being used to classify existing AKI into different phenotypes. Different AI models are used for prediction. The area under the receiver operating characteristic curve values (AUROC) achieved with these models vary and are influenced by several factors, such as the prediction time and the definition of AKI. Most models have an AUROC between 0.650 and 0.900, with lower values for predictions further into the future and when applying Acute Kidney Injury Network (AKIN) instead of KDIGO criteria. Classification into phenotypes already makes it possible to categorize patients into groups with different risks of mortality or requirement of renal replacement therapy (RRT), but the etiologies or therapeutic consequences derived from this are still lacking. However, all the models suffer from AI-specific shortcomings. The use of large databases does not make it possible to promptly include recent changes in therapy and the implementation of new biomarkers in a relevant proportion. For this reason, serum creatinine and urinary output, with their known limitations, dominate current AI models for prediction impairing the performance of the current models. On the other hand, the increasingly complex models no longer allow physicians to understand the basis on which the warning of a threatening AKI is calculated and subsequent initiation of therapy should take place. The successful use of AIs in routine clinical practice will be highly determined by the trust of the physicians in the systems and overcoming the aforementioned weaknesses. However, the clinician will remain irreplaceable as the decisive authority for critically ill patients by combining measurable and nonmeasurable parameters.
Implant will be placed in the maxilla or mandible in a single stage manner and loaded with prosthesis after 6 weeks of healing. Final restorations will take place no later than 4 months following implant placement surgery. The implants will be evaluated yearly for 2 years.
The investigators propose to employ CGM technology in subjects using insulin sensitizers, incretin mimetics and potentiators, insulin secretagogues and insulin to identify the minimum episodic data set that closely mimics CGM data. Specifically, the investigators propose to employ blinded CGM for 2 weeks to capture the diurnal glucose patterns of individuals on different therapeutic regimens. The investigators propose to examine these data to determine whether a specific pattern of SMBG testing derived from these data would provide the same information (e.g., detection of hypoglycemia, measures of glycemic exposure, variability and stability) not possible by relying solely on current SMBG testing schedules.

In preparation for this study the investigators developed a matrix using data collected from previous studies. The matrix summarizes the amount of CGM data the investigators currently possess and indicates where the investigators lack sufficient data to produce SMBG testing schedules based on CGM data. It was determined that 6 cases were needed for each therapy group. An underlying question is whether after the investigators fill this matrix the investigators can discover a common testing pattern for SMBG that would provide sufficient information to uncover the myriad perturbations in glucose patterns that characterize type 2 diabetes. To assure that the investigators are collecting adequate monitoring data, the investigators propose to use Ambulatory Glucose Profile (AGP) analysis of blinded CGM data. This novel approach will enable us to answer the question as to the optimum time and number of SMBG tests sufficient to guide clinical decisions.
The present invention relates to methods of treatment of programmed cell death (apoptosis) through the use of the HSV-1 gene gamma134.5 or the product of its expression, ICP34.5. The gene and its expression have been demonstrated to be required for HSV-1 neurovirulence, and in particular, to act as an inhibitor of neuronal programmed cell death which allows for viral replication. Use of the gene therapy, or the protein itself, can be expected to result in inhibition of programmed cell death in various neurodegenerative diseases. This invention also relates to novel vectors for gene therapy, including modified herpes virus. Methods are presented for conducting assays for substances capable of mimicing, potentiating or inhibiting the expression of gamma134.5 or the activity of ICP34.5. Also, methods are disclosed for the treatment of tumorogenic diseases, including cancer, and for treatment of herpes and other viral infections using inhibitors of gamma134.5 expression or ICP34.5 activity.
FIELD: chemical technology. SUBSTANCE: method for production of hydroxyapatite possessing ANTIMICROBIAL activity includes mixing of hydroxyapatite with inorganic or organic bactericide compounds in water, separation of precipitate, its washing with water and drying. Mixing of hydroxyapatite and bactericide compounds is effected at their mass ratio of 1: (0.2-0.3) and before mixing of ingredients in water, added are disodium ethylenediamine tetraacetate and preparation of enterodose at the rate of 0.03-0.05 and 0.08-0.1 mas.part, respectively, per mas.part of hydroxyapatite. Used as inorganic bactericide compounds is silver nitrate or zinc sulfate and used as organic bactericide compounds are lysozyme or chlorohexydine. EFFECT: produced hydroxyapatite contains bactericide substances of high concentration. 2 cl, 1 tbl
TT-00973-MS tablets will be administered at the starting dose of 2mg. Subsequently, patients will be enrolled according to the standard 3+3 dose escalation design.
The Neurodevelopmental Therapy (NDT) treatment program, which was determined by the physiotherapist to be individual and suitable for the needs of the cases in both groups participating in the study, will continue throughout the study, with 2 sessions per week and 40 minutes each session. The orthoses and assistive devices used by the cases will continue to be used without any changes and no changes will be made to the treatment program.
The primary objective of the prospective observational trial TRELAS (TRoponin ELevation in Acute ischemic Stroke) is to elucidate the underlying pathomechanism of cTnT elevation in acute ischemic stroke in order to give guidance for clinical practise. All consecutive patients with acute MRI- or CT-confirmed ischemic stroke admitting within 72 hours after symptom onset to the Department of Neurology Campus Benjamin Franklin of the university hospital of the Charité will be screened for cTnT elevations suggestive of myocardial infarction (\>0,05 µg/l) on admission and day 2. Patients with increased troponin will undergo diagnostic coronary angiography within 72 hours. Diagnostic findings of coronary angiographies taken out in age- and gender-matched patients presenting with NSTE-ACS (Non-ST-Elevation Acute Coronary Syndrome) to the Division of Cardiology will serve as a control. The primary endpoint of the study will be the occurrence of angiographic culprit lesions indicating focal cardiac damage on the basis of an acute CAD. Secondary endpoints will be the localisation of stroke in the cerebral imaging and ventriculographic findings of wall motion abnormalities suggestive of neurally mediated global cardiac dysfunction.
The same 16 participants will self-administer the oregano product at home for 5 consecutive days. On day 6, participants will return to the study setting, where the procedure described in Arm 3 will be repeated.
A novel method is provided for delivering nucleic acid molecules to the cells of an organism by pulse voltage delivery. The method involves the combination of formulated nucleic acid molecules with devices for injecting the molecules by pulse voltage or an electrical field. Disclosed are compositions and methods for enhancing the administration to and uptake of nucleic acids in a mammal. The methods disclosed provide an increased transfection and/or gene delivery efficiency by enhancing the uptake of formulated nucleic acid molecules by applying an electrical field which destabilizes the cellular membrane thereby opening pores or passageways which allow extracellular material to be introduced to the cell. Also disclosed are examples which demonstate that the combination of formulated nucleic acid molecules and pulse voltage injection methods results in immune responses which are superior to those obtained by conventional means of delivery. Methods for delivery, as well as methods for formulating nucleic acid molecules with various compounds, such as cationic complexing agents, polymeric and non-polymeric formulations, protective, interactive, non-condensing systems are also disclosed.